The QcrB inhibitors TB47 and telacebec do not potentiate the activity of clofazimine in mycobacterium abscessus

Ria Sorayah, Garret C. Moraski, Daniel Barkan, Kevin Pethe*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The antituberculosis drug telacebec is ineffective against Mycobacterium abscessus. A recent study suggested that TB47, a telacebec analogue, potentiated the efficacy of clofazimine against M. abscessus. Here, we report that TB47 not only is ineffective against M. abscessus in vitro but also does not potentiate the activity of clofazimine.

Original languageAmerican English
Article numbere00964-21
JournalAntimicrobial Agents and Chemotherapy
Volume65
Issue number12
DOIs
StatePublished - Dec 2021

Bibliographical note

Publisher Copyright:
Copyright © 2021 American Society for Microbiology. All Rights Reserved.

Keywords

  • Cytochrome bcc:aa
  • Nontuberculous mycobacteria
  • Oxidative phosphorylation
  • Q203
  • Terminal oxidase
  • Tuberculosis

Fingerprint

Dive into the research topics of 'The QcrB inhibitors TB47 and telacebec do not potentiate the activity of clofazimine in mycobacterium abscessus'. Together they form a unique fingerprint.

Cite this